Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
July 15, 2022 16:15 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
July 06, 2022 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
June 21, 2022 16:01 ET
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
May 25, 2022 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
May 16, 2022 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
May 12, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying (“AIM”) Biologicals as a potential...
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
April 19, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO,...
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
April 12, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 ...
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
April 11, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need ...